当前位置： SCI文献检索 > BREAST CANCER RESEARCH期刊下所有文献 > Update on the use of aromatase inhibitors in early-stage breast cancer.

Update on the use of aromatase inhibitors in early-stage breast cancer.

Abstract：

:Aromatase inhibitors are currently included in the 'optimal' management of early-stage breast cancer. Uncertainty remains, however, as to the most appropriate treatment strategy, particularly for newly diagnosed women as they seek to trade off the cost, toxicities and efficacy of the treatment options. Recent publications provide conflicting advice on the role of aromatase inhibitors in the treatment of postmenopausal patients with early-stage hormone receptor-positive breast cancer. This review provides updates on the clinical trials of aromatase inhibitors in early breast cancer and tries to provide practical clinical guidance on their optimal use.

journal_name

Breast Cancer Res

journal_title

Breast cancer research : BCR

authors

Kesisis G,Makris A,Miles D

doi

10.1186/bcr2410

subject

Has Abstract

pub_date

2009-01-01 00:00:00

pages

211

issue

5

eissn

1465-5411

issn

1465-542X

pii

bcr2410

journal_volume

11

pub_type

杂志文章,评审

相关文献

BREAST CANCER RESEARCH文献大全
  • Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts.

    abstract：INTRODUCTION:Rapamycin, an inhibitor of the serine/threonine kinase target of rapamycin, induces G1 arrest and/or apoptosis. Although rapamycin and its analogues are attractive candidates for cancer therapy, their sensitivities with respect to growth inhibition differ markedly among various cancer cells. Using human br...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr1344

    authors： Kasukabe T,Okabe-Kado J,Kato N,Sassa T,Honma Y

    更新日期：2005-01-01 00:00:00

  • Breast tumors: of mice and women.

    abstract：:For the past 20 years the mouse has served as a workhorse for studying the molecular underpinnings of human breast cancer. While some genetically engineered mouse mammary tumor models do not accurately recapitulate human disease (that is, the MMTV-Neu model and HER2-overexpressing human cancers), additional tumor mode...

    journal_title：Breast cancer research : BCR

    pub_type： 评论,社论

    doi：10.1186/bcr2569

    authors： McDermott SP,Wicha MS

    更新日期：2010-01-01 00:00:00

  • Integrin-mediated resistance to epidermal growth factor receptor-targeted therapy: an inflammatory situation.

    abstract：:Targeting the function of epidermal growth factor receptor (EGFR) has failed as an effective clinical option for breast cancer. Understanding the drivers of inherent resistance has been a challenge. One possible mechanism is the acquisition of stem-like properties through the process of epithelial-mesenchymal transiti...

    journal_title：Breast cancer research : BCR

    pub_type： 评论,杂志文章

    doi：10.1186/s13058-014-0448-0

    authors： Brown WS,Wendt MK

    更新日期：2014-09-23 00:00:00

  • The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer.

    abstract：:Testosterone binds to the androgen receptor in target tissue to mediate its effects. Variations in testosterone levels and androgen receptor activity may play a role in the etiology of breast cancer. Here, we review the epidemiologic evidence linking endogenous testosterone to breast cancer risk. Paradoxically, result...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr593

    authors： Lillie EO,Bernstein L,Ursin G

    更新日期：2003-01-01 00:00:00

  • CXCL17-derived CD11b+Gr-1+ myeloid-derived suppressor cells contribute to lung metastasis of breast cancer through platelet-derived growth factor-BB.

    abstract：BACKGROUND:Metastasis is the major cause of death from breast cancer. Colonization and adaption of metastatic cells in distant organs is a rate-limiting step of the cancer spreading. The underlying mechanisms responsible for the colonization of breast cancer to lung metastatic niches are not fully understood. METHODS:...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-019-1114-3

    authors： Hsu YL,Yen MC,Chang WA,Tsai PH,Pan YC,Liao SH,Kuo PL

    更新日期：2019-02-12 00:00:00

  • Activating mutations and senescence secretome: new insights into HER2 activation, drug sensitivity and metastatic progression.

    abstract：:HER2 amplification and overexpression is observed in approximately 20% of breast cancers and is strongly associated with poor prognosis and therapeutic responsiveness to HER2 targeted agents. A recent study by Bose and colleagues suggests that another subset of breast cancer patients without HER2 amplification but wit...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr3406

    authors： Acharyya S

    更新日期：2013-04-23 00:00:00

  • Interaction with adipocyte stromal cells induces breast cancer malignancy via S100A7 upregulation in breast cancer microenvironment.

    abstract：BACKGROUND:Breast adipocytes play important roles in both the development and function of mammary epithelial cells. Therefore, carcinoma-adipose stromal cell (ASC) interactions have been considered pivotal in supporting tumor growth in breast cancer. In addition, it has been demonstrated that the biological features of...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-017-0863-0

    authors： Sakurai M,Miki Y,Takagi K,Suzuki T,Ishida T,Ohuchi N,Sasano H

    更新日期：2017-06-19 00:00:00

  • Ductal approaches to assessment and management of women at high risk for developing breast cancer.

    abstract：:The ductal approach to breast cancer, encompassing nipple aspiration, ductal lavage and duct endoscopy, allows assessment of breast ductal epithelial cells and their local microenvironment in a graded process of increasing invasiveness. Samples of ductal epithelial cells sufficient for cytological diagnosis may be saf...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr759

    authors： Locke I,Mitchell G,Eeles R

    更新日期：2004-01-01 00:00:00

  • Profilin-1 versus profilin-2: two faces of the same coin?

    abstract：:Proteins belonging to the profilin family of actin-binding proteins are considered to be important control elements for actin polymerization and have been linked to a broad spectrum of cellular functions, including cell migration. An intriguing paper recently published in Cancer Cell unveils differential effects of pr...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr3433

    authors： Ding Z,Roy P

    更新日期：2013-06-27 00:00:00

  • Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine.

    abstract：:Genome-wide expression microarray studies have revealed that the biological and clinical heterogeneity of breast cancer can be partly explained by information embedded within a complex but ordered transcriptional architecture. Comprising this architecture are gene expression networks, or signatures, reflecting biochem...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr1662

    authors： Miller LD,Liu ET

    更新日期：2007-01-01 00:00:00

  • Rack1 mediates tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast cancer cells.

    abstract：BACKGROUND:Acquirement of resistance is always associated with a highly aggressive phenotype of tumor cells. Recent studies have revealed that Annexin A2 (Anxa2) is a key protein that links drug resistance and cancer metastasis. A high level of Anxa2 in cancer tissues is correlated to a highly aggressive phenotype. Inc...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-019-1147-7

    authors： Fan Y,Si W,Ji W,Wang Z,Gao Z,Tian R,Song W,Zhang H,Niu R,Zhang F

    更新日期：2019-05-22 00:00:00

  • Initiating breast cancer by PIK3CA mutation.

    abstract：:PIK3CA mutations confer constitutive activation of PI3K, which initiates intracellular kinase signaling cascades that promote cell proliferation and survival. Recent studies by Meyer and colleagues, and Liu and colleagues demonstrate that expression of the H1047R exon 20 mutant of PIK3CA in luminal mammary epithelial ...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr3103

    authors： Miller TW

    更新日期：2012-02-07 00:00:00

  • Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression.

    abstract：:Recent insights into the molecular and cellular mechanisms underlying cancer development have revealed that immune cells functionally regulate epithelial cancer development and progression. Moreover, accumulated clinical and experimental data indicate that the outcome of an immune response toward an evolving breast ne...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr1746

    authors： DeNardo DG,Coussens LM

    更新日期：2007-01-01 00:00:00

  • High-throughput genomic technology in research and clinical management of breast cancer. Molecular signatures of progression from benign epithelium to metastatic breast cancer.

    abstract：:It is generally accepted that early detection of breast cancer has great impact on patient survival, emphasizing the importance of early diagnosis. In a widely recognized model of breast cancer development, tumor cells progress through chronological and well defined stages. However, the molecular basis of disease prog...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr1528

    authors： Rennstam K,Hedenfalk I

    更新日期：2006-01-01 00:00:00

  • Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers.

    abstract：INTRODUCTION:We present a fully automated method for deriving quantitative measures of background parenchymal enhancement (BPE) from breast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and perform a preliminary evaluation of these measures to assess the effect of risk-reducing salpingo-oophorectomy (R...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-015-0577-0

    authors： Wu S,Weinstein SP,DeLeo MJ 3rd,Conant EF,Chen J,Domchek SM,Kontos D

    更新日期：2015-05-19 00:00:00

  • Next-generation transcriptome sequencing of the premenopausal breast epithelium using specimens from a normal human breast tissue bank.

    abstract：INTRODUCTION:Our efforts to prevent and treat breast cancer are significantly impeded by a lack of knowledge of the biology and developmental genetics of the normal mammary gland. In order to provide the specimens that will facilitate such an understanding, The Susan G. Komen for the Cure Tissue Bank at the IU Simon Ca...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr3627

    authors： Pardo I,Lillemoe HA,Blosser RJ,Choi M,Sauder CA,Doxey DK,Mathieson T,Hancock BA,Baptiste D,Atale R,Hickenbotham M,Zhu J,Glasscock J,Storniolo AM,Zheng F,Doerge RW,Liu Y,Badve S,Radovich M,Clare SE,Susan G. Komen f

    更新日期：2014-03-17 00:00:00

  • Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo.

    abstract：INTRODUCTION:Triple-negative breast cancer does not express estrogen and progesterone receptors, and no overexpression/amplification of the HER2-neu gene occurs. Therefore, this subtype of breast cancer lacks the benefits of specific therapies that target these receptors. Today chemotherapy is the only systematic thera...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr2606

    authors： Gründker C,Föst C,Fister S,Nolte N,Günthert AR,Emons G

    更新日期：2010-01-01 00:00:00

  • Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.

    abstract：INTRODUCTION:Inhibition of phosphatidylinositol-3-kinase (PI3K) induces apoptosis when combined with estrogen deprivation in estrogen receptor (ER)-positive breast cancer. The aims of the present study were to identify effective PI3K pathway inhibitor and endocrine therapy combinations, to evaluate the effect of PI3K p...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr2833

    authors： Sanchez CG,Ma CX,Crowder RJ,Guintoli T,Phommaly C,Gao F,Lin L,Ellis MJ

    更新日期：2011-03-01 00:00:00

  • Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways.

    abstract：INTRODUCTION:Although aberrant tyrosine kinase signalling characterises particular breast cancer subtypes, a global analysis of tyrosine phosphorylation in mouse models of breast cancer has not been undertaken to date. This may identify conserved oncogenic pathways and potential therapeutic targets. METHODS:We applied...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-014-0437-3

    authors： Ali NA,Wu J,Hochgräfe F,Chan H,Nair R,Ye S,Zhang L,Lyons RJ,Pinese M,Lee HC,Armstrong N,Ormandy CJ,Clark SJ,Swarbrick A,Daly RJ

    更新日期：2014-09-09 00:00:00

  • The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology G

    abstract：INTRODUCTION:The main prognostic variables in early breast cancer are tumor size, histological grade, estrogen receptor/progesterone receptor (ER/PgR) status, number of positive nodes and human epidermal growth factor receptor 2 (HER2) status. The present study evaluated the prognostic and/or predictive value of vascul...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,随机对照试验

    doi：10.1186/bcr3354

    authors： Linardou H,Kalogeras KT,Kronenwett R,Kouvatseas G,Wirtz RM,Zagouri F,Gogas H,Christodoulou C,Koutras AK,Samantas E,Pectasides D,Bafaloukos D,Fountzilas G

    更新日期：2012-11-12 00:00:00

  • Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.

    abstract：INTRODUCTION:Sustained HER2 signaling at the cell surface is an oncogenic mechanism in a significant proportion of breast cancers. While clinically effective therapies targeting HER2 such as mAbs and tyrosine kinase inhibitors exist, tumors overexpressing HER2 eventually progress despite treatment. Thus, abrogation of ...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr3204

    authors： Ren XR,Wei J,Lei G,Wang J,Lu J,Xia W,Spector N,Barak LS,Clay TM,Osada T,Hamilton E,Blackwell K,Hobeika AC,Morse MA,Lyerly HK,Chen W

    更新日期：2012-06-07 00:00:00

  • Targeting bone metastases starting from the preneoplastic niche: home sweet home.

    abstract：:The metastatic process is a multistep coordinated event with a high degree of efficiency. Specific subpopulations of cancer stem cells, with tumor-initiating and migratory capacity, can selectively migrate towards sites that are able to promote survival and/or proliferation of metastatic tumor cells through a microenv...

    journal_title：Breast cancer research : BCR

    pub_type： 社论,评审

    doi：10.1186/bcr2911

    authors： Santini D,Vincenzi B,Pantano F,Tonini G,Bertoldo F

    更新日期：2011-08-16 00:00:00

  • FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors.

    abstract：BACKGROUND:Breast cancer is a heterogeneous disease. Hence, stratification of patients based on the subtype of breast cancer is key to its successful treatment. Among all the breast cancer subtypes, basal-like breast cancer is the most aggressive subtype with limited treatment options. Interestingly, we found focal adh...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-020-01298-3

    authors： Paul R,Luo M,Mo X,Lu J,Yeo SK,Guan JL

    更新日期：2020-06-03 00:00:00

  • Breast cancer prognostic classification in the molecular era: the role of histological grade.

    abstract：:Breast cancer is a heterogeneous disease with varied morphological appearances, molecular features, behavior, and response to therapy. Current routine clinical management of breast cancer relies on the availability of robust clinical and pathological prognostic and predictive factors to support clinical and patient de...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr2607

    authors： Rakha EA,Reis-Filho JS,Baehner F,Dabbs DJ,Decker T,Eusebi V,Fox SB,Ichihara S,Jacquemier J,Lakhani SR,Palacios J,Richardson AL,Schnitt SJ,Schmitt FC,Tan PH,Tse GM,Badve S,Ellis IO

    更新日期：2010-01-01 00:00:00

  • Genomic signature of parity in the breast of premenopausal women.

    abstract：BACKGROUND:Full-term pregnancy (FTP) at an early age confers long-term protection against breast cancer. Previously, we reported that a FTP imprints a specific gene expression profile in the breast of postmenopausal women. Herein, we evaluated gene expression changes induced by parity in the breast of premenopausal wom...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-019-1128-x

    authors： Santucci-Pereira J,Zeleniuch-Jacquotte A,Afanasyeva Y,Zhong H,Slifker M,Peri S,Ross EA,López de Cicco R,Zhai Y,Nguyen T,Sheriff F,Russo IH,Su Y,Arslan AA,Bordas P,Lenner P,Åhman J,Landström Eriksson AS,Johansson R,H

    更新日期：2019-03-28 00:00:00

  • Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry.

    abstract：:Immunohistochemistry is the most common method for companion diagnostic testing in breast cancer. The readings for estrogen receptor, progesterone receptor, and Her2 directly affect prescription of critical therapies. However, immunohistochemistry is highly sensitive to innumerable pre-analytic variables that result i...

    journal_title：Breast cancer research : BCR

    pub_type： 社论

    doi：10.1186/bcr2782

    authors： Siddiqui S,Rimm DL

    更新日期：2010-01-01 00:00:00

  • Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.

    abstract：BACKGROUND:Developing novel strategies against treatment-resistant triple negative breast cancer (TNBC) cells remains a significant challenge. The ErbB family, including epidermal growth factor receptor (EGFR), plays key roles in metastasis, tumorigenesis, cell proliferation, and drug resistance. Recently, these charac...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-015-0662-4

    authors： Tanei T,Choi DS,Rodriguez AA,Liang DH,Dobrolecki L,Ghosh M,Landis MD,Chang JC

    更新日期：2016-01-12 00:00:00

  • Molecular drivers of lobular carcinoma in situ.

    abstract：:Lobular carcinoma in situ (LCIS) is considered to be a risk factor for the development of invasive breast carcinoma, but it may also be a non-obligate precursor to invasive lobular carcinoma (ILC). Many LCIS lesions do not progress to ILC, and the molecular changes that are necessary for progression from LCIS to ILC a...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/s13058-015-0580-5

    authors： Logan GJ,Dabbs DJ,Lucas PC,Jankowitz RC,Brown DD,Clark BZ,Oesterreich S,McAuliffe PF

    更新日期：2015-06-04 00:00:00

  • Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.

    abstract：BACKGROUND:The tamoxifen metabolite, Z-endoxifen, demonstrated promising antitumor activity in endocrine-resistant estrogen receptor-positive (ER+) breast cancer. We compared the antitumor activity of Z-endoxifen with tamoxifen and letrozole in the letrozole-sensitive MCF7 aromatase expressing model (MCF7AC1), as well ...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-020-01286-7

    authors： Jayaraman S,Hou X,Kuffel MJ,Suman VJ,Hoskin TL,Reinicke KE,Monroe DG,Kalari KR,Tang X,Zeldenrust MA,Cheng J,Bruinsma ES,Buhrow SA,McGovern RM,Safgren SL,Walden CA,Carter JM,Reid JM,Ingle JN,Ames MM,Hawse JR,Goet

    更新日期：2020-05-19 00:00:00

  • Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.

    abstract：INTRODUCTION:Human epidermal growth factor receptor HER3 has been implicated in promoting the aggressiveness and metastatic potential of breast cancer. Upregulation of HER3 has been found to be a major mechanism underlying drug resistance to EGFR and HER2 tyrosine kinase inhibitors and to endocrine therapy in the treat...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-015-0528-9

    authors： Ren XR,Wang J,Osada T,Mook RA Jr,Morse MA,Barak LS,Lyerly HK,Chen W

    更新日期：2015-02-15 00:00:00